Literature DB >> 15328200

Expression of the ELAV-like protein HuR is associated with higher tumor grade and increased cyclooxygenase-2 expression in human breast carcinoma.

Carsten Denkert1, Wilko Weichert, Klaus-Jürgen Winzer, Berit-Maria Müller, Aurelia Noske, Silvia Niesporek, Glen Kristiansen, Hans Guski, Manfred Dietel, Steffen Hauptmann.   

Abstract

PURPOSE: The human ELAV (embryonic lethal abnormal vision)-like protein HuR stabilizes a certain group of cellular mRNAs that contain AU-rich elements in their 3'-untranslated region. Cell culture studies have shown that the mRNA of cyclooxygenase (COX)-2 can be stabilized by HuR. EXPERIMENTAL
DESIGN: To investigate a possible contribution of dysregulation of mRNA stability to the progression of cancer and to overexpression of COX-2, we studied expression of HuR in 208 primary breast carcinomas by immunohistochemistry.
RESULTS: There were two different staining patterns of HuR in tumor tissue of breast carcinomas: nuclear expression was seen in 61% of cases; and an additional cytoplasmic expression was seen in 30% of cases. Expression of HuR was significantly associated with increased COX-2 expression; this association was particularly significant for cytoplasmic HuR expression (P < 0.0005). We further observed a significant association of cytoplasmic (P = 0.002) or nuclear HuR (P = 0.027) expression with increased tumor grade. Only 13% of the grade 1 carcinomas showed cytoplasmic expression of HuR, compared with 46% of the grade 3 carcinomas. There was no significant correlation between HuR expression and other clinicopathological parameters such as histological type, tumor size, or nodal status as well as patient survival.
CONCLUSIONS: Our results suggest that overexpression of HuR in tumor tissue may be part of a regulatory pathway that controls the mRNA stability of several important targets in tumor biology, such as COX-2. Based on our results, additional studies are necessary to investigate whether HuR might be a potential target for molecular tumor therapy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15328200     DOI: 10.1158/1078-0432.CCR-04-0070

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  66 in total

1.  mRNA stability alterations mediated by HuR are necessary to sustain the fast growth of glioma cells.

Authors:  Federico Bolognani; Anne-Isabelle Gallani; Lena Sokol; David S Baskin; Nicole Meisner-Kober
Journal:  J Neurooncol       Date:  2011-09-21       Impact factor: 4.130

2.  The RNA-binding protein HuR opposes the repression of ERBB-2 gene expression by microRNA miR-331-3p in prostate cancer cells.

Authors:  Michael R Epis; Andrew Barker; Keith M Giles; Dianne J Beveridge; Peter J Leedman
Journal:  J Biol Chem       Date:  2011-10-04       Impact factor: 5.157

3.  Post-transcriptional regulation of ERBB2 by miR26a/b and HuR confers resistance to tamoxifen in estrogen receptor-positive breast cancer cells.

Authors:  Sheng Tan; Keshuo Ding; Qing-Yun Chong; Junsong Zhao; Yuan Liu; Yunying Shao; Yuanyuan Zhang; Qing Yu; Zirui Xiong; Weijie Zhang; Min Zhang; Gaopeng Li; Xiaoni Li; Xiangjun Kong; Akhlaq Ahmad; Zhengsheng Wu; Qiang Wu; Xiaodong Zhao; Peter E Lobie; Tao Zhu
Journal:  J Biol Chem       Date:  2017-06-21       Impact factor: 5.157

4.  Expression and distribution of HuR during ATP depletion and recovery in proximal tubule cells.

Authors:  Selvi C Jeyaraj; Duaa Dakhlallah; Stephanie R Hill; Beth S Lee
Journal:  Am J Physiol Renal Physiol       Date:  2006-06-20

5.  HuRrying colon cancer progression.

Authors:  Natalia A Ignatenko; Eugene W Gerner
Journal:  Cancer Biol Ther       Date:  2007-02-02       Impact factor: 4.742

6.  The emerging role of splicing factors in cancer.

Authors:  Ana Rita Grosso; Sandra Martins; Maria Carmo-Fonseca
Journal:  EMBO Rep       Date:  2008-10-10       Impact factor: 8.807

Review 7.  Breast cancer and metabolic syndrome linked through the plasminogen activator inhibitor-1 cycle.

Authors:  Lea M Beaulieu; Brandi R Whitley; Theodore F Wiesner; Sophie M Rehault; Diane Palmieri; Abdel G Elkahloun; Frank C Church
Journal:  Bioessays       Date:  2007-10       Impact factor: 4.345

8.  Cold-inducible RNA-binding protein contributes to human antigen R and cyclin E1 deregulation in breast cancer.

Authors:  Xun Guo; Yuehan Wu; Rebecca S Hartley
Journal:  Mol Carcinog       Date:  2010-02       Impact factor: 4.784

9.  Tandem phosphorylation of serines 221 and 318 by protein kinase Cdelta coordinates mRNA binding and nucleocytoplasmic shuttling of HuR.

Authors:  Anke Doller; Kai Schlepckow; Harald Schwalbe; Josef Pfeilschifter; Wolfgang Eberhardt
Journal:  Mol Cell Biol       Date:  2010-01-19       Impact factor: 4.272

10.  Genetic polymorphisms in RNA binding proteins contribute to breast cancer survival.

Authors:  Rohit Upadhyay; Sandhya Sanduja; Vimala Kaza; Dan A Dixon
Journal:  Int J Cancer       Date:  2012-09-18       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.